Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail
- PMID: 30404629
- PMCID: PMC6223056
- DOI: 10.1186/s12967-018-1678-1
Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail
Abstract
Background: The pharmaceutical industry is in the midst of a productivity crisis and rates of translation from bench to bedside are dismal. Patients are being let down by the current system of drug discovery; of the several 1000 diseases that affect humans, only a minority have any approved treatments and many of these cause adverse reactions in humans. A predominant reason for the poor rate of translation from bench to bedside is generally held to be the failure of preclinical animal models to predict clinical efficacy and safety. Attempts to explain this failure have focused on problems of internal validity in preclinical animal studies (e.g. poor study design, lack of measures to control bias). However there has been less discussion of another key factor that influences translation, namely the external validity of preclinical animal models.
Review of problems of external validity: External validity is the extent to which research findings derived in one setting, population or species can be reliably applied to other settings, populations and species. This paper argues that the reliable translation of findings from animals to humans will only occur if preclinical animal studies are both internally and externally valid. We review several key aspects that impact external validity in preclinical animal research, including unrepresentative animal samples, the inability of animal models to mimic the complexity of human conditions, the poor applicability of animal models to clinical settings and animal-human species differences. We suggest that while some problems of external validity can be overcome by improving animal models, the problem of species differences can never be overcome and will always undermine external validity and the reliable translation of preclinical findings to humans.
Conclusion: We conclude that preclinical animal models can never be fully valid due to the uncertainties introduced by species differences. We suggest that even if the next several decades were spent improving the internal and external validity of animal models, the clinical relevance of those models would, in the end, only improve to some extent. This is because species differences would continue to make extrapolation from animals to humans unreliable. We suggest that to improve clinical translation and ultimately benefit patients, research should focus instead on human-relevant research methods and technologies.
Keywords: External validity; Human-relevant methods; Preclinical animal models; Translation.
Figures
Similar articles
-
Reverse translation of failed treatments can help improving the validity of preclinical animal models.Eur J Pharmacol. 2015 Jul 15;759:14-8. doi: 10.1016/j.ejphar.2015.03.030. Epub 2015 Mar 28. Eur J Pharmacol. 2015. PMID: 25823810 Review.
-
Cardiovascular pharmacotherapy: Innovation stuck in translation.Eur J Pharmacol. 2015 Jul 15;759:200-4. doi: 10.1016/j.ejphar.2015.03.035. Epub 2015 Mar 24. Eur J Pharmacol. 2015. PMID: 25814253 Review.
-
Levelling the Translational Gap for Animal to Human Efficacy Data.Animals (Basel). 2020 Jul 15;10(7):1199. doi: 10.3390/ani10071199. Animals (Basel). 2020. PMID: 32679706 Free PMC article. Review.
-
Inflammatory and Neuropathic Pain From Bench to Bedside: What Went Wrong?J Pain. 2018 Jun;19(6):571-588. doi: 10.1016/j.jpain.2017.12.261. Epub 2018 Jan 4. J Pain. 2018. PMID: 29307749 Review.
-
Validating animal models for preclinical research: a scientific and ethical discussion.Altern Lab Anim. 2010 Jun;38(3):245-8. doi: 10.1177/026119291003800309. Altern Lab Anim. 2010. PMID: 20602541
Cited by
-
Species variations in tenocytes' response to inflammation require careful selection of animal models for tendon research.Sci Rep. 2021 Jun 14;11(1):12451. doi: 10.1038/s41598-021-91914-9. Sci Rep. 2021. PMID: 34127759 Free PMC article.
-
Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects.Nanomaterials (Basel). 2022 Oct 12;12(20):3567. doi: 10.3390/nano12203567. Nanomaterials (Basel). 2022. PMID: 36296756 Free PMC article. Review.
-
Menagerie: A text-mining tool to support animal-human translation in neurodegeneration research.PLoS One. 2019 Dec 17;14(12):e0226176. doi: 10.1371/journal.pone.0226176. eCollection 2019. PLoS One. 2019. PMID: 31846471 Free PMC article.
-
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach?JACC Basic Transl Sci. 2019 Nov 25;4(7):845-854. doi: 10.1016/j.jacbts.2019.10.008. eCollection 2019 Nov. JACC Basic Transl Sci. 2019. PMID: 31998852 Free PMC article.
-
Validation of a functional human AD model with four AD therapeutics utilizing patterned iPSC-derived cortical neurons integrated with microelectrode arrays.Res Sq [Preprint]. 2024 May 20:rs.3.rs-4313679. doi: 10.21203/rs.3.rs-4313679/v1. Res Sq. 2024. Update in: Sci Rep. 2024 Oct 22;14(1):24875. doi: 10.1038/s41598-024-73869-9. PMID: 38826367 Free PMC article. Updated. Preprint.
References
-
- Innovate UK. A non-animal technologies roadmap for the UK: advancing predictive biology. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploa.... Accessed 22 May 2018.
-
- Deloitte. A new future for R&D? Measuring the return from pharmaceutical innovation 2017. 2017. https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-science.... Accessed 10 July 2018.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials